Immunological Recovery: Analysis of Naive (CD45RA+) and Memory (CD45RO+) T Cells Before and at Approximately One Year After Allo-BMT
Individual . | % CD4+ CD45RA+ . | % CD4+ CD45RO+ . | % CD8+ CD45RA+ . | % CD8+ CD45RO+ . |
---|---|---|---|---|
Patient 1 pre-BMT | 34 | 69 | 81 | 21 |
Patient 1 post-BMT | 27 | 71 | 85 | 14 |
Patient 2 pre-BMT | 60 | 34 | 66 | 32 |
Patient 2 post-BMT | 43 | 65 | 54 | 66 |
Reference3-150 value | ||||
0-11 mo | 81 (66-88) | |||
1-6 yr | 71 (66-77) | |||
Donor 1 | 60 | 35 | 82 | 19 |
Donor 2 | 48 | 60 | 40 | 63 |
Reference value | ||||
7-17 yr | 61 (55-67) |
Individual . | % CD4+ CD45RA+ . | % CD4+ CD45RO+ . | % CD8+ CD45RA+ . | % CD8+ CD45RO+ . |
---|---|---|---|---|
Patient 1 pre-BMT | 34 | 69 | 81 | 21 |
Patient 1 post-BMT | 27 | 71 | 85 | 14 |
Patient 2 pre-BMT | 60 | 34 | 66 | 32 |
Patient 2 post-BMT | 43 | 65 | 54 | 66 |
Reference3-150 value | ||||
0-11 mo | 81 (66-88) | |||
1-6 yr | 71 (66-77) | |||
Donor 1 | 60 | 35 | 82 | 19 |
Donor 2 | 48 | 60 | 40 | 63 |
Reference value | ||||
7-17 yr | 61 (55-67) |
The percentage CD45RA+ and CD45RO+ T cells was determined after staining with FITC-labeled anti-CD45RA or anti-CD45RO MoAbs and PE-labeled anti-CD4 or anti-CD8 MoAbs; CD45RA+RO+ T cells were calculated as well.
Age-matched reference values39 are given as median with ranges from 25th to 75th percentiles in parentheses; reference values for CD8+ naive and memory T cells and for CD4+CD45RO+ T cells are not available.